GlassScriptPhysician profile
Sarmistha Kumar
NPI 1720002058
$590.97
in general payments reported to CMS, 2019-2025
16 companies · $23.62 in 2025
The $23.62 reported for 2025 was less than what a typical Physical Medicine & Rehabilitation provider received nationally (typical 2025 total: $138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $141 · 2020: $55.36 · 2021: $41.69 · 2022: $61.66 · 2023: $97.49 · 2024: $170 · 2025: $23.62.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $291.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $291.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $203.24 | 2019-2023 | Tavneos |
| Janssen Biotech, INC. | $56.53 | 2023-2024 | Tremfya |
| Organogenesis INC. | $32.67 | 2024 | |
| Tactile Systems Technology INC | $29.93 | 2021-2022 | |
| Mallinckrodt Enterprises LLC | $28.72 | 2019 | |
| Aurinia Pharma U.S., INC. | $28.46 | 2024 | Lupkynis |
| Lilly USA, LLC | $28.21 | 2024 | Taltz, Olumiant, Zepbound |
| Dexcom, INC. | $25.12 | 2022 | |
| Ascensia Diabetes Care US INC. | $23.84 | 2023 | |
| Genentech USA, INC. | $23.62 | 2025 | Actemra |
| Recordati_rare_diseases_inc. | $21.68 | 2024 | Signifor Lar, Isturisa |
| Abbvie INC. | $21.56 | 2019 | |
| Astellas Pharma US INC | $17.85 | 2024 | Veozah |
| Genzyme Corporation | $17.19 | 2024 | |
| Kyowa Kirin, INC. | $16.73 | 2023 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $15.62 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sarmistha Kumar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.